| Flat View | Sunday, April 05, 2026 |
|
| September 2012 | October 2012 | November 2012 |
| Monday, October 01, 2012 |
|
|
|
|
|
|
| Tuesday, October 02, 2012 |
|
|
|
|
|
|
| Wednesday, October 03, 2012 |
|
|
|
|
|
|
 |
Partnerships With CROs ( 9:00 am )
SMi proudly present their 4th annual 'Partnerships with CROs' Conference
3rd and 4th October 2012, Central London.
About this years conference:
|
This year's conference will look to address the critical subject of improving relationships between Pharma & CROs and how they can work best together to improve drug development and clinical trials.
With the increasing reliance on positive and profitable relationships between these organisations, this conference will aim to bring you opinions, recommendations and case studies from both sides.
This year's programme will look to focus on 5 main areas: Optimising interaction between sponsors and CROs, Developing and executing strategic partnership models, Partner selection, Risk management and Improving communication.
Each session will be addressed by speakers with considerable experience in the field and will address the current issues and proposed solutions faced in each situation.
|
 |
For information on sponsorship and exhibition opportunities, Contact our Sponsorship Department
Last year's attendees included representatives from:
- Bristol-Myers Squibb
- Merck Serono
- Bayer
- INC Research
- Quintiles Ltd
- Biomedical Systems Europe
- Cyprotex Discovery Ltd
- Almac
- BTG
- Alliance Healthcare
- Amilcar International
- Campbell Charles Associates
- ForwaR&D Solutions
- TRIUMPHARMA
|
- Pharmades S.A.S
- PPMLD
- MESM
- Agio Interactive
- KOWA
- University Of Leicester
- PHARSAFER
- Risk Decisions Ltd
- Business Insights
- GW Pharmaceuticals
- Chiltern International Ltd
- Thomson Reuters
- Biocair International Ltd
|
Partnerships with CROs Conference 2011 testimonials:
“Interesting comments on panel discussion”
“Excellent, just what this industry needs”
“Good examples, thought provoking."
“Excellent questions and moderating“
Why should you attend this event?
Discuss the strategic rationale for clinical development outsourcing among the large pharmaceutical companies.
Network and discuss ideas with key decision makers in pharma / biotech / CROs.
Hear from industry experts about the current issues with CRO partnership.
Learn what clinical development capabilities do various companies consider core and noncore, and how is this changing
Investigate to what extent is the design of relationships and associated capabilities aligned with strategic intent
Develop stratergy in relationship structure; standard contract, sophisticated strategic alliance - or something in between.
Hear keynote addresses from:
Tim Highman, Director Outsourcing, Pfizer
Andrew Huxley, Outsourcing Director, Eli Lilly & Co
Gareth Lewis, Director Clinical Research, Pfizer
Prasad Velisetty, Senior Medical Director, Quintiles
Domonic Bowers, Associate Medical Director, Quintiles
Gary Reeves, Clinical Contracts Manager, Biogen Idec
Graeme Ladds, Director, PharSafer
Albert Agro, President, HNZ-Strategy
John Bennett, Director, JABPharma
Volker Ronicke, Vice President, Booz & Co
Peter Behner, Consultant, Booz & Co
Clare Morgan, Director of Industry, NIHR Clinical Research Network Coordinating Centre
Janet Wisely, Chief Executiv, Health Research Authority
Two confirmed half day workshops
Volker Ronicke Vice President & Peter Behner, Consultant, Booz & Co
Graeme Ladds, Director, PharSafer
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk/
| |
| Thursday, October 04, 2012 |
|
|
|
|
|
Partnerships With CROs ( 9:00 am )
SMi proudly present their 4th annual 'Partnerships with CROs' Conference
3rd and 4th October 2012, Central London.
About this years conference:
|
This year's conference will look to address the critical subject of improving relationships between Pharma & CROs and how they can work best together to improve drug development and clinical trials.
With the increasing reliance on positive and profitable relationships between these organisations, this conference will aim to bring you opinions, recommendations and case studies from both sides.
This year's programme will look to focus on 5 main areas: Optimising interaction between sponsors and CROs, Developing and executing strategic partnership models, Partner selection, Risk management and Improving communication.
Each session will be addressed by speakers with considerable experience in the field and will address the current issues and proposed solutions faced in each situation.
|
|
For information on sponsorship and exhibition opportunities, Contact our Sponsorship Department
Last year's attendees included representatives from:
- Bristol-Myers Squibb
- Merck Serono
- Bayer
- INC Research
- Quintiles Ltd
- Biomedical Systems Europe
- Cyprotex Discovery Ltd
- Almac
- BTG
- Alliance Healthcare
- Amilcar International
- Campbell Charles Associates
- ForwaR&D Solutions
- TRIUMPHARMA
|
- Pharmades S.A.S
- PPMLD
- MESM
- Agio Interactive
- KOWA
- University Of Leicester
- PHARSAFER
- Risk Decisions Ltd
- Business Insights
- GW Pharmaceuticals
- Chiltern International Ltd
- Thomson Reuters
- Biocair International Ltd
|
Partnerships with CROs Conference 2011 testimonials:
“Interesting comments on panel discussion”
“Excellent, just what this industry needs”
“Good examples, thought provoking."
“Excellent questions and moderating“
Why should you attend this event?
Discuss the strategic rationale for clinical development outsourcing among the large pharmaceutical companies.
Network and discuss ideas with key decision makers in pharma / biotech / CROs.
Hear from industry experts about the current issues with CRO partnership.
Learn what clinical development capabilities do various companies consider core and noncore, and how is this changing
Investigate to what extent is the design of relationships and associated capabilities aligned with strategic intent
Develop stratergy in relationship structure; standard contract, sophisticated strategic alliance - or something in between.
Hear keynote addresses from:
Tim Highman, Director Outsourcing, Pfizer
Andrew Huxley, Outsourcing Director, Eli Lilly & Co
Gareth Lewis, Director Clinical Research, Pfizer
Prasad Velisetty, Senior Medical Director, Quintiles
Domonic Bowers, Associate Medical Director, Quintiles
Gary Reeves, Clinical Contracts Manager, Biogen Idec
Graeme Ladds, Director, PharSafer
Albert Agro, President, HNZ-Strategy
John Bennett, Director, JABPharma
Volker Ronicke, Vice President, Booz & Co
Peter Behner, Consultant, Booz & Co
Clare Morgan, Director of Industry, NIHR Clinical Research Network Coordinating Centre
Janet Wisely, Chief Executiv, Health Research Authority
Two confirmed half day workshops
Volker Ronicke Vice President & Peter Behner, Consultant, Booz & Co
Graeme Ladds, Director, PharSafer
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk/
| |
|
8th Annual Quality & OPEX In Pharma & Biotech ( 8:30 am )
This two-day conference will embrace the whole pharma quality process and deliver you the key insights on the link between quality performance and business strategy, achieving quality-operational excellence synergies, quality risk and management tools & techniques, lean thinking in manufacturing and across the entire organization and many more.
Contact Info : +421 257 272 165
Email :
Url: http://pharma.flemingeurope.com/quality/
| |
|
|
| Friday, October 05, 2012 |
|
|
|
8th Annual Quality & OPEX In Pharma & Biotech ( 8:30 am )
This two-day conference will embrace the whole pharma quality process and deliver you the key insights on the link between quality performance and business strategy, achieving quality-operational excellence synergies, quality risk and management tools & techniques, lean thinking in manufacturing and across the entire organization and many more.
Contact Info : +421 257 272 165
Email :
Url: http://pharma.flemingeurope.com/quality/
| |
|
|
|
|
| Saturday, October 06, 2012 |
|
8th Annual Quality & OPEX In Pharma & Biotech ( 8:30 am )
This two-day conference will embrace the whole pharma quality process and deliver you the key insights on the link between quality performance and business strategy, achieving quality-operational excellence synergies, quality risk and management tools & techniques, lean thinking in manufacturing and across the entire organization and many more.
Contact Info : +421 257 272 165
Email :
Url: http://pharma.flemingeurope.com/quality/
| |
|
|
|
|
|
|
| Sunday, October 07, 2012 |
|
|
|
|
|
|
| Monday, October 08, 2012 |
|
|
|
|
|
|
| Tuesday, October 09, 2012 |
|
|
|
|
|
|
| Wednesday, October 10, 2012 |
|
|
|
|
|
|
| Thursday, October 11, 2012 |
|
|
|
|
|
|
| Friday, October 12, 2012 |
|
|
|
|
|
|
| Saturday, October 13, 2012 |
|
|
|
|
|
|
| Sunday, October 14, 2012 |
|
|
|
|
|
|
| Monday, October 15, 2012 |
|
|
|
|
|
|
| Tuesday, October 16, 2012 |
|
|
|
|
|
|
| Wednesday, October 17, 2012 |
|
|
|
|
|
2nd Annual World Orphan Drug Congress ( 8:00 am )
17 - 18 October 2012, Barcelona, Spain
When orphan drugs are still at the early stages of development,the latest and most accurate information is required for the drug to advance efficiently.
Fleming Europe organizes the 2nd Annual Orphan Drug Congress 2012,where worldwide pharmaceutical experts will share their experiences and insight.
KEY TOPICS
Successful development plan for Orphan Drug
Regulatory challenges surrounding Orphan drug development
Developing patient registries
Commercial aspects of orphan drug development
Patient perspective
+ PLUS
Ms Sharon Terry (President and CEO of Genetic Alliance) will open the first day of the conference with keynote presentation “A team of teams: Orphan drug development”
President of OrphaNet Ms Segolene Ayme will present International Rare Disease Research Initiative
Development of orphan and ultra orphan drugs to prevent, diagnose and treat rare diseases is very challenging dueto its niche nature. On the other hand, rare diseases show the potential of less intense competition, faster and less expensive development, and lower marketing spend on a small, highly motivated audience.
Email :
Url: http://pharma.flemingeurope.com/orphan-drug-congress
| |
|
|
| Thursday, October 18, 2012 |
|
|
|
|
|
2nd Annual World Orphan Drug Congress ( 8:00 am )
17 - 18 October 2012, Barcelona, Spain
When orphan drugs are still at the early stages of development,the latest and most accurate information is required for the drug to advance efficiently.
Fleming Europe organizes the 2nd Annual Orphan Drug Congress 2012,where worldwide pharmaceutical experts will share their experiences and insight.
KEY TOPICS
Successful development plan for Orphan Drug
Regulatory challenges surrounding Orphan drug development
Developing patient registries
Commercial aspects of orphan drug development
Patient perspective
+ PLUS
Ms Sharon Terry (President and CEO of Genetic Alliance) will open the first day of the conference with keynote presentation “A team of teams: Orphan drug development”
President of OrphaNet Ms Segolene Ayme will present International Rare Disease Research Initiative
Development of orphan and ultra orphan drugs to prevent, diagnose and treat rare diseases is very challenging dueto its niche nature. On the other hand, rare diseases show the potential of less intense competition, faster and less expensive development, and lower marketing spend on a small, highly motivated audience.
Email :
Url: http://pharma.flemingeurope.com/orphan-drug-congress
| |
|
|
| Friday, October 19, 2012 |
|
|
|
|
|
2nd Annual World Orphan Drug Congress ( 8:00 am )
17 - 18 October 2012, Barcelona, Spain
When orphan drugs are still at the early stages of development,the latest and most accurate information is required for the drug to advance efficiently.
Fleming Europe organizes the 2nd Annual Orphan Drug Congress 2012,where worldwide pharmaceutical experts will share their experiences and insight.
KEY TOPICS
Successful development plan for Orphan Drug
Regulatory challenges surrounding Orphan drug development
Developing patient registries
Commercial aspects of orphan drug development
Patient perspective
+ PLUS
Ms Sharon Terry (President and CEO of Genetic Alliance) will open the first day of the conference with keynote presentation “A team of teams: Orphan drug development”
President of OrphaNet Ms Segolene Ayme will present International Rare Disease Research Initiative
Development of orphan and ultra orphan drugs to prevent, diagnose and treat rare diseases is very challenging dueto its niche nature. On the other hand, rare diseases show the potential of less intense competition, faster and less expensive development, and lower marketing spend on a small, highly motivated audience.
Email :
Url: http://pharma.flemingeurope.com/orphan-drug-congress
| |
|
|
| Saturday, October 20, 2012 |
|
|
|
|
|
|
| Sunday, October 21, 2012 |
|
|
|
|
|
|
| Monday, October 22, 2012 |
|
|
|
|
|
|
|
COPD: Novel Therapeutics And Management Strategies ( 9:00 am )
 |
|
|
SMi are proud to present their 4th annual COPD: Novel Therapeutics and Management Strategies conference convening in Central LondonMonday 22nd and Tuesday 23rd 2012. Consisting of an industry led programme with academic keynote presentations, this event will be the perfect opportunity to hear presentations on the latest hot topics surrounding COPD and to network with key industry professionals. on
This conference continues to promote increased awareness of COPD and explores ways to improve quality of life for patients, prevention of exacerbations and analyses the new treatment techniques developed over the previous twelve months.
SMi's 4th annual conference on COPD will provide attendees with a complete view of the field and will focus on novel combination therapies, the latest insights in drug developments and clinical trial design, as well as discussing health economics of COPD drugs, this informative event will bring together key opinion leaders in the field to provide attendees with an in-depth look into current advances in COPD.
This year's agenda will provide an unparalleled opportunity for debate and problem solving of key challenges currently facing the field, allowing attendees to discuss progress in the area and exchange ideas moving forward, ensures a truly comprehensive treatment of the most important issues
|
|
Why should you attend this event?
Key Benefits of Attending:
- Consider developments in the modeling and management of exacerbations of COPD
- Evaluate unique complexities of COPD pathophysiology - compare and contrast COPD with Asthma to improve your understanding of what makes COPD unique and needing of particualr attention.
- Develop combination and oxygen therapies within COPD - learn about triple therapies and novel therapies within the treatment of COPD
- Hear from leading industry professionals on the current clinical trials process and rapid proof of concept
- Analyse all phases of the discovery process, from pre-clinical modelling, phase 2 studies all the way through to modelling clincal outcomes.
- Network with and learn from key industry professional and research leading academics
- Discuss the latest in health economics for COPD drugs
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk/
| |
| Tuesday, October 23, 2012 |
|
|
|
|
|
COPD: Novel Therapeutics And Management Strategies ( 9:00 am )
|
|
|
SMi are proud to present their 4th annual COPD: Novel Therapeutics and Management Strategies conference convening in Central LondonMonday 22nd and Tuesday 23rd 2012. Consisting of an industry led programme with academic keynote presentations, this event will be the perfect opportunity to hear presentations on the latest hot topics surrounding COPD and to network with key industry professionals. on
This conference continues to promote increased awareness of COPD and explores ways to improve quality of life for patients, prevention of exacerbations and analyses the new treatment techniques developed over the previous twelve months.
SMi's 4th annual conference on COPD will provide attendees with a complete view of the field and will focus on novel combination therapies, the latest insights in drug developments and clinical trial design, as well as discussing health economics of COPD drugs, this informative event will bring together key opinion leaders in the field to provide attendees with an in-depth look into current advances in COPD.
This year's agenda will provide an unparalleled opportunity for debate and problem solving of key challenges currently facing the field, allowing attendees to discuss progress in the area and exchange ideas moving forward, ensures a truly comprehensive treatment of the most important issues
|
|
Why should you attend this event?
Key Benefits of Attending:
- Consider developments in the modeling and management of exacerbations of COPD
- Evaluate unique complexities of COPD pathophysiology - compare and contrast COPD with Asthma to improve your understanding of what makes COPD unique and needing of particualr attention.
- Develop combination and oxygen therapies within COPD - learn about triple therapies and novel therapies within the treatment of COPD
- Hear from leading industry professionals on the current clinical trials process and rapid proof of concept
- Analyse all phases of the discovery process, from pre-clinical modelling, phase 2 studies all the way through to modelling clincal outcomes.
- Network with and learn from key industry professional and research leading academics
- Discuss the latest in health economics for COPD drugs
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk/
| |
|
|
| Wednesday, October 24, 2012 |
|
|
|
|
|
|
|
Point Of Care Diagnostics - Market Opportunities And Technology Trends ( 9:00 am )
|
SMi are proud to present their 9th annual Point of Care Diagnostics: Market Opportunities and Technology Trends24th and 25th of October, 2012. conference, scheduled for the
With point of care constantly at the forefront of the biotechnology and healthcare markets, the need for up to date information on both the emerging technologies, and the market opportunities is paramount. Rapid testing in all areas of healthcare, from primary care to the emergency services is becoming increasingly expected, and successful point of care technology can revolutionise our ability to create this fast, personalised medicine. Challenges still remain, however, about the logistics of companion diagnostics, the legitimacy of patient independence and the redistribution of profit within the healthcare technology sector.
The ultimate question of whether we can create a treatment specific for a patient, rather than a disease necessitates an ability to communicate with key opinion leaders, successful companies and academic leaders within the field, and conferences such as this are an integral part of that process.
|
 |
“Excellent! Fun, informative, futuristic!” Director POC of Roche Diagnostics
“Highly relevant” Chief Executive, ABA – France
“Excellent” Scientia Advisors
Why should you attend this event?
· Network with diagnostic manufacturers, pharmaceutical specialists and key healthcare members and practitioners working with POC technology
· Explore the economics, markets, developments, connectivity and other key topics within the POC industry
· Learn about the current market pulls and emerging technologies and the ways that they affect medical diagnostics and the healthcare industry
· Discuss the POC industry, its potential expansion into wider markets and its future in the NHS and in European healthcare
· See new emerging technologies, and speak to the people at the forefront of development, manufacture and usage
Our expert speaker line-up also includes:
- Hans Winker, Senior Director Translational Research, Oncology, Johnson & Johnson
- Thomas Li, Senior Director, Technology Management, Roche Diagnostics, Singapore
- Gilbert Greub, Chief of Medicine, Institute of Microbiology
- David Huckle, President & Director General, ABA – France
- Christopher Lowe, Director of the Institute of Biotechnology, University of Cambridge
- Mohammad Al-Ubaydli, CEO, Patients Know Best
- Chris Price, Visiting Professor in Clinical Biochemistry, University of Oxford
- Gillian Hall, POCT Coordinator, Royal Free Hospital
- Terenzio Facchinetti, Manager Business Development, UL Life and Health Sciences Europe
- Stéphan Cohen-Bacrie, Specialist, Hôpital la Timone
- Richard Gill, Board Director, Launchpad Venture Group
- Loes Segarink, Researcher, University of Twente
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk/
| |
| Thursday, October 25, 2012 |
|
|
|
|
|
Point Of Care Diagnostics - Market Opportunities And Technology Trends ( 9:00 am )
|
SMi are proud to present their 9th annual Point of Care Diagnostics: Market Opportunities and Technology Trends24th and 25th of October, 2012. conference, scheduled for the
With point of care constantly at the forefront of the biotechnology and healthcare markets, the need for up to date information on both the emerging technologies, and the market opportunities is paramount. Rapid testing in all areas of healthcare, from primary care to the emergency services is becoming increasingly expected, and successful point of care technology can revolutionise our ability to create this fast, personalised medicine. Challenges still remain, however, about the logistics of companion diagnostics, the legitimacy of patient independence and the redistribution of profit within the healthcare technology sector.
The ultimate question of whether we can create a treatment specific for a patient, rather than a disease necessitates an ability to communicate with key opinion leaders, successful companies and academic leaders within the field, and conferences such as this are an integral part of that process.
|
|
“Excellent! Fun, informative, futuristic!” Director POC of Roche Diagnostics
“Highly relevant” Chief Executive, ABA – France
“Excellent” Scientia Advisors
Why should you attend this event?
· Network with diagnostic manufacturers, pharmaceutical specialists and key healthcare members and practitioners working with POC technology
· Explore the economics, markets, developments, connectivity and other key topics within the POC industry
· Learn about the current market pulls and emerging technologies and the ways that they affect medical diagnostics and the healthcare industry
· Discuss the POC industry, its potential expansion into wider markets and its future in the NHS and in European healthcare
· See new emerging technologies, and speak to the people at the forefront of development, manufacture and usage
Our expert speaker line-up also includes:
- Hans Winker, Senior Director Translational Research, Oncology, Johnson & Johnson
- Thomas Li, Senior Director, Technology Management, Roche Diagnostics, Singapore
- Gilbert Greub, Chief of Medicine, Institute of Microbiology
- David Huckle, President & Director General, ABA – France
- Christopher Lowe, Director of the Institute of Biotechnology, University of Cambridge
- Mohammad Al-Ubaydli, CEO, Patients Know Best
- Chris Price, Visiting Professor in Clinical Biochemistry, University of Oxford
- Gillian Hall, POCT Coordinator, Royal Free Hospital
- Terenzio Facchinetti, Manager Business Development, UL Life and Health Sciences Europe
- Stéphan Cohen-Bacrie, Specialist, Hôpital la Timone
- Richard Gill, Board Director, Launchpad Venture Group
- Loes Segarink, Researcher, University of Twente
Contact Info : General Enquiries:
SMi Group Ltd,
2nd Floor South, Harling House,
47-51 Great Suffolk Street,
London, SE1 0BS,
United Kingdom.
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Client Services:
Tel: +44 (0) 870 9090 711
Fax: +44 (0) 870 9090 712
Email :
Url: http://www.smi-online.co.uk/
| |
|
|
| Friday, October 26, 2012 |
|
|
|
|
|
|
| Saturday, October 27, 2012 |
|
|
|
|
|
|
| Sunday, October 28, 2012 |
|
|
|
|
|
|
| Monday, October 29, 2012 |
|
|
|
|
|
|
| Tuesday, October 30, 2012 |
|
|
|
|
|
|
|
|
| Wednesday, October 31, 2012 |
|
|
|
|
